Johnson & Johnson
Johnson & Johnson Announces Q3 2024 Financial Results and Updates Guidance
Summary
On October 15, 2024, Johnson & Johnson reported its Q3 2024 financial results, with reported sales growth of 5.2% to $22.5 billion. Despite a 34.3% decrease in diluted EPS to $1.11 due to a one-time special charge and acquired IPR&D, adjusted operational sales grew by 6.3% and adjusted operational EPS decreased by 9.0% to $2.42. The company updated its full-year 2024 guidance, reflecting improved performance and the impact of the acquisition of V-Wave.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement